Department of Neurosurgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo, Japan.
Front Immunol. 2024 Jan 15;15:1328375. doi: 10.3389/fimmu.2024.1328375. eCollection 2024.
Glioblastoma (GBM) is a highly lethal brain tumor. The effectiveness of temozolomide (TMZ) treatment in GBM is linked to the methylation status of O6-methyl-guanine DNA methyltransferase () promoter. Patients with unmethylated promoter have limited treatment options available. Consequently, there is a pressing need for alternative therapeutic strategies for such patients.
Data, including transcriptomic and clinical information, as well as information on promoter methylation status in primary GBM, were obtained from The Cancer Genome Atlas (TCGA) (n=121) and Chinese Glioma Genome Atlas (CGGA) (n=83) datasets. Samples were categorized into high and low expression groups, MGMT-high (MGMT-H) and MGMT-low (MGMT-L) tumors. A comprehensive transcriptome analysis was conducted to explore the tumor-immune microenvironment. Furthermore, we integrated transcriptome data from 13 GBM patients operated at our institution with findings from tumor-infiltrating lymphocyte (TIL) cultures, specifically investigating their response to autologous tumors.
Gene signatures associated with various immune cells, including CD8 T cells, helper T cells, B cells, and macrophages, were noted in MGMT-H tumors. Pathway analysis confirmed the enrichment of immune cell-related pathways. Additionally, biological processes involved in the activation of monocytes and lymphocytes were observed in MGMT-H tumors. Furthermore, TIL culture experiments showed a greater presence of tumor-reactive T cells in MGMT-H tumors compared to MGMT-L tumors. These findings suggest that MGMT-H tumors has a potential for enhanced immune response against tumors mediated by CD8 T cells.
Our study provides novel insights into the immune cell composition of MGMT-H tumors, which is characterized by the infiltration of type 1 helper T cells and activated B cells, and also the presence of tumor-reactive T cells evidenced by TIL culture. These findings contribute to a better understanding of the immune response in MGMT-H tumors, emphasizing their potential for immunotherapy. Further studies are warranted to investigate on the mechanisms of expression and antitumor immunity.
胶质母细胞瘤(GBM)是一种高度致命的脑肿瘤。替莫唑胺(TMZ)治疗 GBM 的效果与 O6-甲基鸟嘌呤 DNA 甲基转移酶()启动子的甲基化状态有关。启动子未甲基化的患者治疗选择有限。因此,对于此类患者,迫切需要替代治疗策略。
从癌症基因组图谱(TCGA)(n=121)和中国胶质瘤基因组图谱(CGGA)(n=83)数据集中获取包括转录组和临床信息以及原发性 GBM 中启动子甲基化状态信息的数据。将样本分为高和低表达组、MGMT 高(MGMT-H)和 MGMT 低(MGMT-L)肿瘤。进行了全面的转录组分析以探索肿瘤免疫微环境。此外,我们整合了我们机构的 13 名 GBM 患者的转录组数据和肿瘤浸润淋巴细胞(TIL)培养的结果,特别研究了它们对自体肿瘤的反应。
在 MGMT-H 肿瘤中观察到与各种免疫细胞(包括 CD8 T 细胞、辅助 T 细胞、B 细胞和巨噬细胞)相关的基因特征。通路分析证实了免疫细胞相关通路的富集。此外,在 MGMT-H 肿瘤中观察到与单核细胞和淋巴细胞激活相关的生物学过程。此外,TIL 培养实验表明,与 MGMT-L 肿瘤相比,MGMT-H 肿瘤中存在更多的肿瘤反应性 T 细胞。这些发现表明,MGMT-H 肿瘤具有通过 CD8 T 细胞介导的针对肿瘤的增强免疫反应的潜力。
我们的研究提供了关于 MGMT-H 肿瘤免疫细胞组成的新见解,其特征是 1 型辅助 T 细胞和激活的 B 细胞浸润,以及 TIL 培养证明的肿瘤反应性 T 细胞存在。这些发现有助于更好地了解 MGMT-H 肿瘤中的免疫反应,强调了其免疫治疗的潜力。需要进一步的研究来研究表达和抗肿瘤免疫的机制。